Mustang BioMBIO
About: Mustang Bio Inc is a clinical-stage biopharmaceutical company focused on translating today's medical breakthroughs in cell and gene therapy into potential cures for hematologic cancers, solid tumors, and rare genetic diseases. Its pipeline is currently focused on the core areas of gene therapies for rare genetic disorders, chimeric antigen receptor (CAR) engineered T cell (CAR T) therapies for hematologic malignancies, and CAR T therapies for solid tumors.
Employees: 80
Fund manager confidence
Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)
299% more capital invested
Capital invested by funds: $207K [Q3] → $827K (+$619K) [Q4]
83% more first-time investments, than exits
New positions opened: 11 | Existing positions closed: 6
50% more repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 4
20% more funds holding
Funds holding: 25 [Q3] → 30 (+5) [Q4]
7.16% more ownership
Funds ownership: 2.42% [Q3] → 9.58% (+7.16%) [Q4]
Research analyst outlook
We haven’t received any recent analyst ratings for MBIO.
Financial journalist opinion









